- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
AbelsonTaylor for Astellas's AmBisome
Pharmaceutical Executive
When Astellas' AmBisome marketing campaign needed an upgrade to set it apart from the competition, AbelsonTaylor came up with a "fierce yet friendly" promotional tactic.
SMILING BEAR
AbelsonTaylor
BRAND AmBisome CLIENT Astellas FROM LEFT: Janet Kleve, creative director; Tim Brennan, senior art director; Donna Arey, senior copywriter; Lauren Cunningham, senior art director; Caren Spigland, senior copywriter
When Astellas' AmBisome marketing campaign needed an upgrade to set it apart from the competition, AbelsonTaylor came up with a "fierce yet friendly" promotional tactic. AmBisome was already viewed as a powerful way to combat invasive fungal infections, but the excellent safety of the drug compared to others' containing amphotericin B was often overlooked. AT's creative team devised a campaign that captured this quality in an eye-catching and effective display. The smiling bear translates AmBisome's brand essence from "power that's safer" to "friendlier power." This idea is also reflected in the bold and clever slogan: "Fierce on fungus. Kinder to kidneys."
Bright ideas don't always come easily, though. "We needed to communicate our position to the physician, and make sure the sales force was on board," says AT's Janet Kleve. "Since we were dealing with a serious disease state, we needed to weigh the tone of the branding and the promise of the product with physicians."
They made the grade. According to Kleve, physicians found the campaign memorable, and sales reps were ready and willing to use it.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
